Colorectal cancer disease information and screening guidelines
This information is intended for U.S. Healthcare Professionals only.
Although colorectal cancer (CRC) is the second leading cause of cancer-related death, it can be prevented 9 out of 10 times through early detection with colonoscopy.1 Combined with an effective preparation and quality cleansing, colonoscopy is the preferred way to prevent CRC because some polyps or growths can be detected and removed before they become cancerous.
American College of Gastroenterology guidelines for CRC screening
In 2008, the American College of Gastroenterology (ACG) endorsed updated guidelines for CRC screening. Colonoscopy every 10 years, beginning at age 50, remains the preferred CRC screening method. To simplify screening discussions with patients and increase the likelihood that patients will choose to be screened, the ACG prefers that clinicians present patients with
a recommended screening strategy rather than a menu of options. The strategic screening methods are divided into cancer prevention tests and cancer detection tests.
CRC screening recommendations for patients at average risk2
|
|
Preferred recommendations
|
Alternative recommendations
|
|
Cancer prevention tests
|
Colonoscopy
every 10 years beginning at age 50.
- Screening should begin at age 45 in African Americans.
- Screening should begin earlier for patients with extreme smoking habits or obesity.
|
Flexible sigmoidoscopy every 5-10 years
or computed tomographic colonography
(virtual colonoscopy) every 5 years
|
|
Cancer detection tests
|
Fecal immunochemical test
every year for patients who decline colonoscopy or another cancer prevention
test
|
Hemoccult Sensa every year or
fecal DNA testing every 3 years
|
CRC screening recommendations for patients at high risk
For patients with a family history of CRC or advanced adenoma diagnosed younger than 60 years of age, the ACG guidelines recommend colonoscopy every 5 years beginning at age 40 or 10 years younger than the age at diagnosis of the youngest affected relative. If the cancer was diagnosed after the age of 60, the ACG recommends average-risk screening.
ACG guidelines recommend split dosing
Almost one third of bowel preparations are inadequate, hindering the detection of small and flat lesions.3 The ACG guidelines recommend split-dosing colonoscopy preparations with at least half of the dose given on the day of the colonoscopy for optimal visualization of the ascending colon and cecum.2
To view the complete guidelines, visit
http://gi.org/media/releases/acg2009crcguideline.pdf.
References
Get Adobe Acrobat Reader
MOVIPREP® (PEG-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid for oral solution) is indicated for cleansing of the
colon as a preparation for colonoscopy in adults 18 years of age or older. MOVIPREP is contraindicated in patients who have had a severe hypersensitivity reaction
to any of its components. MOVIPREP should be used with caution in patients using concomitant medications that increase the risk of electrolyte abnormalities, in patients with known or suspected hyponatremia,
severe ulcerative colitis, ileus, gastrointestinal obstruction or perforation, gastric retention, toxic colitis, toxic megacolon, or glucose-6-phosphate dehydrogenase deficiency. In clinical trials, abdominal
distention, anal discomfort, thirst, nausea, and abdominal pain were the most common adverse reactions to MOVIPREP administration. MOVIPREP contains a maximum of 2.33 mg of phenylalanine per treatment.
Consult with your physician to see if this product is right for you.
For complete Prescribing Information, please click here.
For product information, adverse event reports, and product complaint reports please call:
Salix Product Information Call Center
Phone: 1-800-508-0024
Fax: 1-510-595-8183
Email: